Tango Therapeutics, Inc. Depreciation
Tango Therapeutics, Inc. (TNGX) reported Depreciation of $888.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-11
- Tango Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $425.00K, a 32.00% decline year-over-year.
- Tango Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $463.00K, a 25.56% decline year-over-year.
- Tango Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $479.00K, a 22.74% decline year-over-year.
- Tango Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $555.00K, a 10.77% decline year-over-year.
- Tango Therapeutics, Inc. depreciation for fiscal 2025 was $2.28M, a 8.72% decline from fiscal 2024.
- Tango Therapeutics, Inc. depreciation for fiscal 2024 was $2.50M, a 3.48% increase from fiscal 2023.
- Tango Therapeutics, Inc. depreciation for fiscal 2023 was $2.42M, a 50.19% increase from fiscal 2022.
- Tango Therapeutics, Inc. depreciation for fiscal 2022 was $1.61M, a 79.26% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $425.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $888.00K 10-Q · filed 2026-08-11 | $1.37M derived: sum of 3 quarters · filed 2026-08-11 | $1.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $463.00K 10-Q · filed 2026-05-13 | $942.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.50M derived: sum of 3 quarters · filed 2026-05-13 | $2.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $479.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.03M derived: sum of 2 quarters · filed 2026-03-05 | $1.66M derived: sum of 3 quarters · filed 2026-08-11 | $2.28M 10-K · filed 2026-03-05 |
| 2025-09-30 | $555.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.18M derived: sum of 2 quarters · filed 2026-08-11 | $1.80M 10-Q · filed 2025-11-04 | $2.42M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $625.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.25M 10-Q · filed 2026-08-11 | $1.87M derived: sum of 3 quarters · filed 2026-08-11 | $2.49M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $622.00K 10-Q · filed 2026-05-13 | $1.24M derived: sum of 2 quarters · filed 2026-05-13 | $1.86M derived: sum of 3 quarters · filed 2026-05-13 | $2.50M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $620.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.24M derived: sum of 2 quarters · filed 2026-03-05 | $1.87M derived: sum of 3 quarters · filed 2026-03-05 | $2.50M 10-K · filed 2026-03-05 |
| 2024-09-30 | $622.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.25M derived: sum of 2 quarters · filed 2025-11-04 | $1.88M 10-Q · filed 2025-11-04 | $2.50M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $632.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.26M 10-Q · filed 2025-08-05 | $1.87M derived: sum of 3 quarters · filed 2026-03-05 | $2.49M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $625.00K 10-Q · filed 2025-05-12 | $1.24M derived: sum of 2 quarters · filed 2026-03-05 | $1.85M derived: sum of 3 quarters · filed 2026-03-05 | $2.46M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $617.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.23M derived: sum of 2 quarters · filed 2026-03-05 | $1.83M derived: sum of 3 quarters · filed 2026-03-05 | $2.42M 10-K · filed 2026-03-05 |
| 2023-09-30 | $613.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.22M derived: sum of 2 quarters · filed 2024-11-06 | $1.80M 10-Q · filed 2024-11-06 | $2.37M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $604.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.19M 10-Q · filed 2024-08-07 | $1.75M derived: sum of 3 quarters · filed 2025-02-27 | $2.17M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $581.00K 10-Q · filed 2024-05-08 | $1.15M derived: sum of 2 quarters · filed 2025-02-27 | $1.57M derived: sum of 3 quarters · filed 2025-02-27 | $1.88M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $570.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $987.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.30M derived: sum of 3 quarters · filed 2025-02-27 | $1.61M 10-K · filed 2025-02-27 |
| 2022-09-30 | $417.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $729.00K derived: sum of 2 quarters · filed 2023-11-08 | $1.04M 10-Q · filed 2023-11-08 | $1.29M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $312.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $621.00K 10-Q · filed 2023-08-07 | $877.00K derived: sum of 3 quarters · filed 2023-08-07 | $1.08M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $309.00K 10-Q · filed 2023-05-09 | $565.00K derived: sum of 2 quarters · filed 2023-05-09 | $765.00K derived: sum of 3 quarters · filed 2023-05-09 | $977.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $256.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $456.00K derived: sum of 2 quarters · filed 2023-03-27 | $668.00K derived: sum of 3 quarters · filed 2023-03-27 | $897.00K 10-K · filed 2023-03-27 |
| 2021-09-30 | $200.00K 10-Q · filed 2021-11-09 | $412.00K derived: sum of 2 quarters · filed 2022-08-10 | $641.00K 10-Q · filed 2022-11-10 | $807.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-06-30 | $212.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $416.00K 10-Q · filed 2022-08-10 | $607.00K derived: sum of 3 quarters · filed 2022-08-10 | $807.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $204.00K 10-Q · filed 2022-05-11 | $395.00K derived: sum of 2 quarters · filed 2022-05-11 | $595.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $191.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $391.00K derived: sum of 2 quarters · filed 2022-03-28 | $718.00K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $200.00K 10-Q · filed 2021-11-09 | $527.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |